Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11391
Title: Urothelial cancers: using biology to improve outcomes.
Austin Authors: Pezaro, Carmel;Liew, Mun Sem;Davis, Ian D
Affiliation: Joint Ludwig Austin Oncology Unit, Austin Hospital LTB6, Heidelberg, VIC 3084, Australia
Issue Date: 1-Jan-2012
Publication information: Expert Review of Anticancer Therapy; 12(1): 87-98
Abstract: Urothelial carcinoma (transitional cell carcinoma) is the most common malignancy of the urinary tract. Urothelial carcinoma of the bladder is a common disease but has traditionally been underrepresented in both public awareness and cancer research. The purpose of this review is to provide an outline of the recent updates in understanding of urothelial cancer etiology, particularly with regards to lower tract muscle-invasive disease, and to discuss the identified mutations in high- and low-grade disease. We will consider evidence for the current systemic therapies for muscle-invasive and metastatic disease and review the targeted therapies under investigation for advanced urothelial cancer.
Gov't Doc #: 22149435
URI: http://ahro.austin.org.au/austinjspui/handle/1/11391
DOI: 10.1586/era.11.195
URL: https://pubmed.ncbi.nlm.nih.gov/22149435
Type: Journal Article
Subjects: Carcinoma, Transitional Cell.drug therapy.pathology
Clinical Trials as Topic
Humans
Neoplasm Invasiveness
Neoplasm Metastasis
Randomized Controlled Trials as Topic
Urinary Bladder Neoplasms.drug therapy.pathology
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Dec 6, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.